Reviva Pharma's schizophrenia drug succeeds in late-stage study
Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings RVPH.O said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Savio D'Souza) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture